Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

Haematologica. 2020 Oct 1;105(10):e519. doi: 10.3324/haematol.2019.238808.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Purines / therapeutic use
  • Quality of Life*
  • Quinazolinones / therapeutic use

Substances

  • Purines
  • Quinazolinones
  • idelalisib